Clinical Trial Update: A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients [Phase 3]

View source ↗

Summary

This entry notes that Hanmi's HGP2102 is in a Phase 3 trial for essential hypertension and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• HGP2102

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Hypertension | Phase 3 | Status: RECRUITING